About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

A Study of TAK-881 in Healthy Adults

A Phase 1, Single-Dose, Single-Center, Open-Label, Three-Arm Study to Assess the Tolerability and Safety of Immune Globulin Subcutaneous (Human), 20% Solution With Recombinant Human Hyaluronidase (TAK-881) at Various Infusion Rates in Healthy Adult Subject

NCT05059977•Takeda

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Healthy Volunteers

Interventions

TAK-881

Locations

1

United States

Locations (1)

Clinical Pharmacology of Miami

Hialeah, Florida, United States

Key Dates

Start Date

October 12, 2021

Primary Completion Date

April 12, 2022

Completion Date

April 12, 2022

Last Updated

January 12, 2024

Related Studies

RECRUITINGPhase 1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

RECRUITINGPhase 1

A Study of ENX-104 in Healthy Participants

NCT07472361

Healthy Volunteers

RECRUITINGPhase 1

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

NCT06823947

Healthy Volunteers Essential Hypertension

RECRUITINGPhase 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110

Healthy Volunteers, Pulmonary Arterial Hypertension

RECRUITINGPhase 1

Single-dose,First-in-human of KLA478

NCT07240675

Healthy Volunteers

View all related studies

Sponsors

Lead Sponsor

Takeda

Collaborators

Takeda Development Center Americas, Inc.
Baxalta Innovations GmbH, now part of Shire

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions